Iptacopan in IgA Nephropathy: Slowing Kidney Failure

Dr. James Whitfield

...and when you have a thirty five year old sitting across from you in clinic, with their protein levels stubbornly high despite maximum RAS inhibitors, you, uh, you know where that trajectory goes. Without intervention, they are looking at kidney failure within a decade.

Dr. Elena Rodriguez

Right, because standard supportive therapy, your ACE inhibitors or ARBs, even with about nineteen point three percent of patients in this new trial on SGLT2 inhibitors at baseline, it just, er, it doesn't shut down the actual inflammatory driver in IgA nephropathy.

Dr. James Whitfield

Exactly. The immune complexes deposit right in the glomerulus, and that triggers the alternative complement pathway. Persistent inflammation, downstream fibrosis, gradual loss of function. Which brings us to the APPLAUSE IgAN phase 3 trial, published in The New England Journal of Medicine by Dr. Jonathan Barratt and his team.

Dr. Elena Rodriguez

They enrolled four hundred and seventy seven adults, right? All with biopsy proven IgA nephropathy, eGFR at or above thirty mL per minute, and severe proteinuria, meaning a urine protein to creatinine ratio of at least one gram per gram.

Dr. James Whitfield

Exactly. Randomized to oral iptacopan, two hundred milligrams twice daily, versus placebo. And over twenty four months, the annualized eGFR slope, the measure of kidney function loss, was minus three point one zero mL per minute per year for iptacopan compared to minus six point twelve for placebo.

Dr. Elena Rodriguez

That is an annual preservation of three point zero two mL per minute per year! P value less than zero point zero zero one.

Dr. James Whitfield

It is massive. In fact, iptacopan significantly slows kidney function decline and reduces the risk for kidney failure compared with placebo. We saw a forty three percent reduction in composite kidney failure events, twenty one point four percent in the iptacopan group versus thirty three point five percent on placebo, with a hazard ratio of zero point five seven.

Dr. Elena Rodriguez

Biologically, what iptacopan is doing here is so clean. It is a selective factor B inhibitor. Factor B is essential for forming the C3 convertase in the alternative complement pathway. So by targeting factor B, you act like an upstream circuit breaker. You stop the amplification loop without completely shutting down the classical or lectin pathways that you need for general immune defense.

Dr. James Whitfield

And clinically, Elena, think about what preserving three mL per minute of eGFR every single year actually means for a young patient. If a thirty five year old is losing six mL per minute per year, they hit end stage renal disease and need dialysis or a transplant in, say, ten years. Cut that rate in half, to three mL per minute per year, and you have just added another decade or more of independence off dialysis. That is life changing context.

Dr. Elena Rodriguez

You know, what I find fascinating from a regulatory perspective is how this trial bridged surrogate endpoints to hard clinical outcomes. Remember, iptacopan got accelerated FDA approval based on early surrogate data.

Dr. James Whitfield

The nine month proteinuria data, right?

Dr. Elena Rodriguez

Yes! An interim analysis at 9 months found a significant 38.3% reduction in UPCR for patients assigned to iptacopan. But clinicians always wonder, does dropping urine protein actually translate to saving nephrons two years down the road?

Dr. James Whitfield

And now these twenty four month results confirm it did. Not only did eGFR slope hold up, but the need for rescue therapy dropped from thirteen point four percent in the placebo arm down to four point six percent with iptacopan. So the surrogate marker predicted real clinical benefit.

Dr. Elena Rodriguez

But, uh, James, we, we have to talk about the immunological cost. Complement inhibition is never a free lunch. While overall adverse events were fairly balanced, eighty seven point zero percent versus eighty nine point one percent, the serious infection numbers caught my eye.

Dr. James Whitfield

Six point seven percent in the iptacopan arm versus two point one percent on placebo. More than a threefold increase.

Dr. Elena Rodriguez

Driven largely by pneumonia and encapsulated bacterial pathogens, including two confirmed cases of Streptococcus pneumoniae. Mechanistically, that makes complete sense. The alternative complement pathway provides rapid opsonization and forms the membrane attack complex to clear encapsulated bacteria. When you block factor B, you blunt that primary defense system.

Dr. James Whitfield

Which is why rigorous vaccination against Neisseria meningitidis and Streptococcus pneumoniae prior to starting therapy is absolutely nonnegotiable. You cannot skip that step.

Dr. Elena Rodriguez

Right. And we also have to recognize the trial boundary conditions. APPLAUSE IgAN specifically targeted high risk patients with proteinuria at or above one gram per gram. We do not have trial data showing benefit in lower risk, low proteinuria patients where the infection risk might outweigh the renal benefit.

Dr. James Whitfield

Exactly. For our highest risk patients, iptacopan gives us a powerful new tool to alter the trajectory of a devastating disease, provided we manage the infection risk vigilance closely. Good chatting about this, Elena.

Dr. Elena Rodriguez

Always a pleasure, James. Talk soon.